The CAR-T Blog
“Join me as we explore, discover, read, and review the most current and vital content and information about CLL and its surrounding issues.”
On May 7, 2012 I took my first dose of PCI-32765 at Ohio State University, in Columbus, OH as part of a phase 1 trial of the drug that would later revolutionize the treatment of CLL as ibrutunib. But for the first several years it was known only by
Dr. Brian Koffman explains his post-CAR-T bone marrow biopsy which will employ next generation sequencing by means of clonoSEQ testing that can find as few as one in a million CLL cells, not by looking for the cells themselves, as flow cytometry does when it scans the cells’ surface
Our own Dr. Koffman was interviewed at ASH 2019 about importance of attending ASH for advocates, his own research, his highlights from ASH and much more. You can watch it here.
Dr. Brian Koffman gives his updated medical report, post CAR-T for CLL (chronic lymphocytic leukemia: “My first imaging (MRI) since leaving Seattle for home post CAR-T was a few weeks ago, about 21 months post CAR-T and it found “that all my lymph nodes had shrunk to normal size
In the Dec 23, 2019 episode of Hidden Forces, “Demetri Kofinas speaks with Brian Koffman, a doctor turned CLL patient, whose patient education and advocacy efforts have given hope and encouragement to CLL cancer patients everywhere.” “Brian Koffman is extraordinary, in many ways. He’s extraordinary in the medical sense
Lab results one and half years post CAR-T therapy are very good. My absolute lymphocyte count is low- about 1,000. Not much room for cancer to hide there. I am not anemic. Hemoglobin is in the middle of the normal range for the first time in forever. My platelets
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
